Floatz logo

POLY(ACETYL, ARGINYL)GLUCOSAMINE (25000-50000 MW)

Respiratory Tract Disease

Synspira, Inc.OtherPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Respiratory Tract Disease cohort.

Asset / SponsorPhaseRating
Carboplatin
Nanfang Hospital, Southern Medical University
Phase 3BB
Rocuronium
Ziekenhuis Oost-Limburg
Phase 4BB
.GAMMA.-CYCLODEXTRIN, 6A,6B,6C,6D,6E,7F,6G,6H-OCTAKIS-S-(2-CARBOXYETHYL)-6A,6B,6C,6D,6E,7F,6G,6H-OCTATHIO-
Ziekenhuis Oost-Limburg
Phase 4BB
NEOSTIGMINE
Ziekenhuis Oost-Limburg
Phase 4BB
NEOSTIGMINE
Coastal Anesthesiology Consultants
Phase 4BB

View all 33 →

Same molecule, other indications

POLY(ACETYL, ARGINYL)GLUCOSAMINE (25000-50000 MW) is also rated in:

pneumonitisDormant
CC
Indicative ·
43 / 100
View asset →
burkholderia infectious diseaseDormant
CC
Indicative ·
43 / 100
View asset →
Lung InflammationDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →